Literature DB >> 8797863

CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus.

G D Roye1, R B Myers, D Brown, R Poczatek, S W Beenken, W E Grizzle.   

Abstract

The molecular events involved in the development of esophageal dysplasia and carcinoma are poorly understood. We examined the expression of CD44, a cell-adhesion molecule, in normal and dysplastic epithelia and in squamous-cell carcinoma (SCC) of the esophagus. A monoclonal antibody (MAb) which recognized all CD44 isoforms and 2 MAbs specific to the CD44v3 and CD44v6 splice variants were used to detect CD44 isoforms in 50 archival specimens. A semi-quantitative scoring system based on the extent and intensity of the immunostaining was used to quantify CD44 expression. In normal epithelium, expression of CD44 was strongest in the basal-cell layer and weak or absent in surface cells. Expression of CD44 was increased in dysplastic epithelium as compared with normal epithelium. The extent of this increase correlated directly with the severity of dysplasia. CD44 was expressed in all SCCs, but the extent and intensity of immunostaining varied with areas of tumor differentiation. The well-differentiated components showed greater CD44 expression than the moderately and poorly differentiated components. The patterns of expression of CD44v3 and CD44v6 were strikingly similar to that of total CD44 in normal, dysplastic and malignant esophageal epithelia. Thus, changes in expression of these splice variants likely account to some extent for the changes in total CD44 expression observed in the dysplastic and malignant transformation of the esophagus. Our results suggest that changes in the expression of CD44 may be involved in the development of esophageal dysplasia as well as SCC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797863     DOI: 10.1002/(SICI)1097-0215(19960822)69:4<254::AID-IJC2>3.0.CO;2-W

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma.

Authors:  T Nozoe; S Kohnoe; T Ezaki; A Kabashima; Y Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-11       Impact factor: 4.553

2.  Squamous dysplasia--the precursor lesion for esophageal squamous cell carcinoma.

Authors:  Philip R Taylor; Christian C Abnet; Sanford M Dawsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

3.  Validation of esophageal squamous cell carcinoma candidate genes from high-throughput transcriptomic studies.

Authors:  Qiang Du; Wusheng Yan; Victoria H Burton; Stephen M Hewitt; Lemin Wang; Nan Hu; Philip R Taylor; Michael D Armani; Sumana Mukherjee; Michael R Emmert-Buck; Michael A Tangrea
Journal:  Am J Cancer Res       Date:  2013-08-14       Impact factor: 6.166

4.  Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44.

Authors:  Jiang-Sha Zhao; Wen-Jie Li; Di Ge; Pei-Jing Zhang; Jing-Jing Li; Chun-Lai Lu; Xiao-Dan Ji; Dong-Xian Guan; Hong Gao; Li-Yan Xu; Eng-Ming Li; Harmik Soukiasian; H Phillip Koeffler; Xiao-Fan Wang; Dong Xie
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

5.  Role of MAML1 in targeted therapy against the esophageal cancer stem cells.

Authors:  Meysam Moghbeli; Hooman Mosannen Mozaffari; Bahram Memar; Mohammad Mahdi Forghanifard; Mehran Gholamin; Mohammad Reza Abbaszadegan
Journal:  J Transl Med       Date:  2019-04-16       Impact factor: 5.531

6.  Evaluation of CD44 and TGF-B Expression in Oral Carcinogenesis.

Authors:  Narges Ghazi; Nasrollah Saghravanian; Mohammad Taghi Shakeri; Mounes Jamali
Journal:  J Dent (Shiraz)       Date:  2021-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.